Last reviewed · How we verify
Evolocumab Prefilled Syringe
Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.
Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream. Used for Hypercholesterolemia (primary and secondary prevention of cardiovascular events), Familial hypercholesterolemia.
At a glance
| Generic name | Evolocumab Prefilled Syringe |
|---|---|
| Sponsor | University of Erlangen-Nürnberg Medical School |
| Drug class | PCSK9 inhibitor (monoclonal antibody) |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that degrades LDL receptors on hepatocytes. By binding to and inhibiting PCSK9, evolocumab prevents LDL receptor degradation, leading to increased expression of LDL receptors on liver cells and enhanced uptake of LDL cholesterol from the blood. This results in significant reductions in circulating LDL cholesterol levels.
Approved indications
- Hypercholesterolemia (primary and secondary prevention of cardiovascular events)
- Familial hypercholesterolemia
Common side effects
- Injection site reactions
- Nasopharyngitis
- Upper respiratory tract infection
- Influenza
- Back pain
Key clinical trials
- Effect of Evolocumab on Vascular Function (PHASE4)
- Reducing Intracranial atheroSclErosis With Repatha (PHASE4)
- Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: